|
| Status |
Public on Mar 09, 2018 |
| Title |
Enhancement of Arterial Specification in Human Pluripotent Stem Cell Cultures Promotes Definitive Hematoendothelial Program with Broad Myelolymphoid Potential |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Identification of the regulators that lead to arterial specification with definitive hematopoietic potential should help to design strategies to recapitulate HSC development from human pluripotent stem cells (hPSCs). Here, using ETS1 conditional H1 hESC line, we found that ETS1 induction at the mesodermal stage of differentiation dramatically enhances the arterial specification in hPSC cultures and formation of DLL4+CXCR4+/- arterial HE with lymphoid potential and the capacity to produce red blood cells with high expression of BCL11a and b-globin. ETS1 effect was mediated through upregulation of NOTCH signaling. Together, these findings demonstrated that promotion of arterial specification in cultures could aid in generation of definitive hematopoiesis from hPSCs.
|
| |
|
| Overall design |
We engineered H1 human embryonic stem cells (hESC) carrying doxycycline (DOX)-inducible ETS1-P2A-EGFP transgene (iETS1-hESCs) and differentiated them to endothelial and hematopoietic cells in chemically defined conditions
|
| |
|
| Contributor(s) |
Slukvin I, Park MA, Swanson S, Moskvin O |
| Citation(s) |
29791856, 29739946 |
| Submission date |
Mar 20, 2017 |
| Last update date |
May 21, 2019 |
| Contact name |
Oleg Moskvin |
| Organization name |
University of Wisconsin-Madison
|
| Street address |
1220 Capitol Court
|
| City |
Madison |
| State/province |
WI |
| ZIP/Postal code |
53715 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (12)
|
| GSM2544620 |
VE-cadherin+ endothelial cells with No Dox treatment at Day4 of Differentiation |
| GSM2544621 |
VE-cadherin+ endothelial cells with iETS1 expression (Day 2-4 of Dox) at Day4 of Differentiation |
| GSM2748255 |
DLL4- HE cells with 1.5ug/ml Dox treatment at Day5 of Differentiation |
| GSM2748256 |
DLL4+ HE cells with 1.5ug/ml Dox treatment at Day5 of Differentiation |
| GSM2748257 |
DLL4- HE cells with 1ug/ml Dox treatment at Day5 of Differentiation |
| GSM2748258 |
DLL4+ HE cells with 1ug/ml Dox treatment at Day5 of Differentiation |
| GSM2748259 |
DLL4- HE cells with 2ug/ml Dox treatment at Day5 of Differentiation |
| GSM2748260 |
DLL4+ HE cells with 2ug/ml Dox treatment at Day5 of Differentiation |
| GSM2748261 |
DLL4- HE cells at Day5 of Differentiation |
| GSM2748262 |
DLL4+ HE cells at Day5 of Differentiation |
| GSM2748263 |
DLL4- HE cells with No Dox treatment at Day5 of Differentiation |
| GSM2748264 |
DLL4+ HE cells with No Dox treatment at Day5 of Differentiation |
|
| Relations |
| BioProject |
PRJNA379808 |
| SRA |
SRP102181 |
Less...
More...